Figure 1 | British Journal of Cancer

Figure 1

From: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Figure 1

Prognostic significance of BCL2 according to the level of BCL2 expression. (A) Immunohistochemical evaluation of BCL2 staining intensity. Immunohistochemical analysis of BCL2 from the SEARCH series (BCL2 antibody, Dako clone 124, 1 : 200). (B) Kaplan–Meier curve of cumulative survival according to BCL2 staining intensity. 0=no BCL2 staining: n=1646, HR=1.00; 1=weak BCL2 staining intensity: n=1100, HR=0.76, 95% CI 0.66–0.88, P<0.001; 2=moderate BCL2 staining intensity: n=1921, HR=0.55, 95% CI 0.49–0.63, P<0.001; 3=strong BCL2 staining intensity: n=3022, HR=0.45, 95% CI 0.40–0.51, P<0.001.

Back to article page